Study of iparomlimab and tuvonralimab with olaparib and paclitaxel for early high-risk triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a targeted therapy (olaparib) and chemotherapy (paclitaxel) before surgery for people with an aggressive type of early breast cancer called triple-negative breast cancer. It is for those whose tumors have a specific genetic feature called HRD-positive, which may make the cancer more sensitive to these treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have early-stage triple-negative breast cancer that has not spread to distant organs, but lymph nodes may be involved or the tumor is larger than 2 cm.
- Your tumor has been tested and is HRD-positive (a sign that DNA repair in the cancer cells is faulty).
- You have at least one measurable tumor that can be tracked with scans.
- You are in generally good health (able to take care of yourself and out of bed most of the day).
- You have adequate organ function as shown by blood tests (normal blood cell counts, kidney and liver function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, QL1706 (an immunotherapy) and olaparib (a targeted therapy), for people with a specific type of advanced breast cancer called triple-negative that has a DNA repair problem (HRD). It may be an option if you've had 1 or 2 prior treatments but haven't tried similar drugs before.
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
This trial tests a new drug called retlirafusp alfa (a type of immunotherapy) combined with chemotherapy or another drug called fuzuloparib (a PARP inhibitor) for triple-negative breast cancer that is advanced or newly diagnosed at stage II-III. The goal is to see if this combination can shrink tumors or improve outcomes compared to standard treatments.
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
Hear when a new Triple Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.